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Background: In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of
age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella
epidemiology were investigated.
Methods: Data on varicella vaccinations, cases and complications were collected from annual parent surveys
(2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric
hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of
cases and hospitalisations were estimated.
Results: Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38%, 51%,
53%, 53%, 66% and 68%); second-dose coverage reached 59% in the 2011 survey. A monthly mean of 82 (62%) practices
participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use
of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases
<17 years of age. The mean number of cases decreased by 67% in two steps, from 6.6 (95%CI 6.1-7.0) per 1,000 patient
contacts in season 2006/07 to 4.2 (95%CI 3.9-4.6) in 2007/08 and 4.0 (95%CI 3.6-4.3) in 2008/09, and further to 2.3 (95%CI
2.0-2.6) in 2009/10 and 2.2 (95%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd
protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in
2010/11. Vaccinated cases increased from 0.3 (95%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95%CI 0.3-0.5)
until 2008/09 and decreased to 0.2 (95%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases,
mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5%)
with neurological complications and one (0.6%) fatality due to varicella pneumonia. Incidence of hospitalisations
decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years
of age.
Conclusions: Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program,
even with still suboptimal vaccination coverage.
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In the absence of a general vaccination programme, vari-
cella (chickenpox), the primary infection with the varicella
zoster virus (VZV), affects almost all children in the course
of their childhood [1]. Varicella is usually mild in immuno-
competent children, but occasionally there are severe com-
plications and even fatalities [1-5]. To reduce general
morbidity as well as the number of severe cases, several
countries outside Europe (Australia, Canada, Costa Rica,
Ecuador, Israel, New Zealand, Oman, Panama, Qatar,
Saudi-Arabia, South Korea, Taiwan, the United Arab Emir-
ates, Uruguay and USA) [1,6-8] as well as some European
countries (Germany, Greece, Latvia, Luxembourg) [8-11]
and regions (seven out of 21 in Italy [12], two out of 17 in
Spain [13]) have introduced routine varicella vaccination
during the last two decades.
The United States was the first country to implement
routine varicella immunization for all children in 1995.
Vaccination coverage in children 19-35 months of age
reached 85% by 2003, and one-dose immunization was
highly effective in reducing varicella-associated morbidity,
ambulatory visits, hospitalisations and mortality, including
indirect benefits observed in non-vaccinated groups [e.g.,
14-17]. However, varicella outbreaks were still observed
even in populations with high vaccination coverage; hence,
the recommendations were expanded to a routine two-
dose schedule in 2006 [18].
Germany was the first country in Europe to introduce
funded nationwide varicella vaccination as part of the
routine childhood vaccination schedule. In 2004, the
German Advisory Committee on Vaccinations (STIKO)
recommended vaccination with a single dose in children
aged 11-14 months. Additionally, catch-up vaccinations
for all susceptible children and adolescents were
recommended, with two doses in children over 13 years
of age [19]. Two monovalent varicella vaccines were
available in Germany at the time of recommendation. A
combined measles-mumps-rubella-varicella (MMR-V)
vaccine, licensed with a two-dose schedule for all age
groups, was available in 2006 [20]. In autumn 2008, li-
censure for both monovalent varicella vaccines was also
changed to a two-dose schedule. In July 2009, the
STIKO recommendation was adapted accordingly, with
the second dose recommended preferably at 15-23
months of age [21].
Data on varicella vaccination coverage and the effects of
the vaccination program is limited thus far in Germany.
Based on extrapolation from statutory health insurance data
varicella vaccination coverage for children 24 months of age
in Germany was roughly estimated as 80% in 2009 [22].
Until March 2013, there was no statutory notification on
varicella disease in Germany. From 2005 to 2009, nation-
wide voluntary sentinel surveillance of about 900 paediatri-
cians and general practitioners estimated a reduction invaricella cases by 63% in children <5 years of age, and by
55% in all age groups. This sentinel surveillance aimed at
trends in varicella epidemiology, but could not provide es-
timates on varicella incidence as it was not population-
based [20].
In October 2006 regional surveillance on children in a
defined area (Munich) was implemented, the ‘Bavarian
Varicella Surveillance Project’ (BaVariPro) [23]. In the
first part of the project, annual cross-sectional parent
surveys on random samples of children 18 to 36 months
of age were performed from 2006 to 2011 to determine
vaccination coverage in the area [24]. In the second part,
routine varicella vaccination in paediatric practices and
its impact on the frequency and age distribution of vari-
cella cases was investigated from October 2006 to
September 2011, to estimate incidences of varicella cases
and to determine the frequency of varicella in vaccinated
children, and of complicated varicella cases. In a third
part of the project, database records from paediatric
hospitals in the surveillance area were evaluated to iden-
tify varicella patients admitted during the years 2005 to
2009, and annual incidences for varicella-associated
hospitalisations were calculated.
Methods
Surveillance area and study population
The area under surveillance was the City of Munich and its
surrounding districts. The study population from 2005 to
2010 consisted of a yearly average of 237,700 children <17
years of age, with an increase in annual births from about
15,930 in 2005 to 17,370 in 2010. Approximately 77% of
the paediatric population live in Munich City (Bavarian
Statistical Office) [25]. At the start of surveillance, there
were 132 registered paediatric practices and four paediatric
hospitals in the area of Munich.
Parent surveys
From 2006 to 2011, annual parent surveys were conducted
at the end of each year to determine varicella vaccination
coverage in children 18 to 36 months of age in the surveil-
lance area, following the method described by Streng et al.
[24]. For each survey, a random sample of 600 children
aged 18-36 months was drawn from central inhabitant
registries. The parents received a questionnaire by mail, in-
cluding questions on history of varicella disease and the
varicella and measles vaccination status as recorded in the
child’s vaccination booklet (vaccine trade names and dates
of vaccinations).
Paediatric practice surveillance
In Germany, medical care and vaccination of pre-school
children is mainly provided by paediatric practices. In
September 2006, all 132 paediatric practices in the sur-
veillance area were invited to participate in the regional
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pated in January 2009 were replaced, aiming at a con-
stant number of about 75 to 85 regularly reporting
practices per month. At the start of surveillance, all par-
ticipating practices provided a questionnaire on charac-
teristics of the practice and the paediatrician. Practice
surveillance was conducted from October 2006 to
September 2011, thus including five completed varicella
seasons (October to September).
Practices were asked to report all varicella patients
according to the case definitions of the German ‘Work-
ing Group on Varicella’ [20]: a) children with a typical or
atypical exanthema of the skin or mucous membranes
compatible with varicella; b) children who had been
varicella-vaccinated at any time before the start of vari-
cella exanthema; c) children with varicella or its compli-
cations, who had to be hospitalized, or required antiviral
or antibiotic therapy, or showed neurological symptoms,
or showed involvement of organs other than the skin, or
showed thrombocytopenia. Laboratory confirmation of
varicella zoster virus was encouraged but not requested.
Varicella cases were reported aggregated by age group
(<1, 1-4, 5-9, and 10-16 years of age) on monthly ques-
tionnaires. Additionally, the practices documented the
monthly numbers of varicella and/or measles vaccina-
tions (first and second dose), separately for monovalent
varicella vaccine, measles-mumps-rubella (MMR) and
combined MMR-varicella vaccine (MMR-V). Vaccina-
tions were also documented stratified by age group (<2,
2-9, and 10-16 years of age). Finally, practices reported
the total number of patient contacts during the respect-
ive month. In addition, pseudonymous, single-case
questionnaires were collected for children with varicella
complications, including basic demographic data, type
of varicella complication, varicella vaccination status,
chronic underlying diseases, hospitalisation, and out-
come. The practices received a small compensation for
each returned questionnaire. Missing, incomplete or im-
plausible questionnaires were followed up by phone.Paediatric hospital database queries
All paediatric hospitals (n = 4) in Munich were invited to
participate in database queries on patients <17 years of
age with an ICD-10 (International Classification of
Diseases, 10th version) discharge diagnosis of varicella
(B01.0 – B01.9) as primary or as any secondary diagno-
sis, admitted between January 1st, 2005 and December
31st, 2009. Basic demographic data (including age, gen-
der, first three digits of postal code), date of hospitalisa-
tion, as well as the primary and all discharge diagnoses
were collected. All reported varicella patients treated in
Munich paediatric hospitals were included in the ana-
lysis of patient characteristics.Ethical consideration
The Bavarian Varicella Surveillance Project was ap-
proved by the Bavarian Data Protection Office and the
University Ethics Committees of Munich and Wurzburg.
For the parent surveys informed consent was required.
Data analysis
Data from the parent surveys and practice surveillance
were entered twice into a Microsoft Access 2003 database
and reconciled. Data received from hospitals were entered
into a Microsoft Excel 2003 database. All data were trans-
ferred into SPSS 20.0 or SAS 9.2 for statistical analysis.
Data from the parent surveys and the hospitals were
analysed descriptively per year, data from the practice sur-
veillance per varicella season (October to September), pro-
viding percentages, mean and 95% confidence intervals
(95%CI) or median with inter-quartile range (IQR). Com-
parisons across subgroups were assessed using Pearson’s
Chi2-test for categorical data, or Mantel-Haenszel’s Chi2-
test for linear trend, and the Kruskal-Wallis test for quanti-
tative data using a 0.05 level of significance, respectively.
Univariate time series regression models were applied to
analyse the age-specific time-course of varicella cases in
the practices, following the statistical methods described
by Höhle et al. [22]. Relative reduction factors (RRF) from
season to season were estimated per age group from
model-predicted values, with overall percentage of reduc-
tion across the seasons calculated as 1-(RRF2/1 x RRF3/2 x
RRF4/3 x RRF5/4) for each age group [22].
For incidence estimates of varicella cases per season
based on the paediatric practice surveillance the popula-
tion at risk was assumed to be the resident paediatric
population in Munich (City and surrounding districts) at
31st of December [25]. Minimum incidences for each
season and stratified by age group were calculated based
solely on the number of observed cases in the participat-
ing practices. In a second approach, incidences were es-
timated taking into account varicella cases outside the
scope of the present surveillance. Firstly, varicella cases
in non-participating paediatric practices (36%-40%) were
estimated, assuming a similar average number of vari-
cella cases in a participating and a non-participating
practice per season. Secondly, estimates on paediatric
varicella cases treated by general practitioners (GP) were
included. Based on a GP survey on about 10% of all reg-
istered GP practices in Munich (Streng et al.; unpub-
lished data), it was estimated that, overall, the total
number of more than 1,000 GP practices in the area
contribute a total of 35% of all varicella cases <17 years
of age for whom a physician was consulted. Thirdly,
varicella cases not treated by a physician were estimated
as (at least) 20% of all varicella cases per season, based
on the results of the parent surveys on toddlers from the
Munich area [24].
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hospitalisations based on the data from Munich paediat-
ric hospitals, the population at risk was assumed to be
the resident paediatric population in Munich City at 31st
of December [25]. From all reported varicella patients,
only children with a postal code specific for Munich City
(803 to 819) were selected (as Munich District codes also
cover some adjacent geographical areas). Furthermore, all
patients with a primary diagnosis considered unrelated to
varicella disease were excluded (for example, patients with
overt surgical codes). For the years during which only three
out of all four paediatric hospitals participated, the total
annual number of paediatric varicella hospitalisations in
Munich was estimated based on the number of hospital beds.
For those varicella seasons for which complete data
from all paediatric hospitals were available, data from
Munich City patients provided by the hospitals (age, sex,
month of admittance, varicella complication diagnoses)
were matched with single-case reports on patients reported
as hospitalised by the paediatric practices, in order to evalu-
ate the degree of underreporting of hospitalisations by the
practice surveillance.Results
Parent surveys - vaccination coverage
For the surveys from 2006 to 2011, between 301 (50.2%)
and 372 (62.0%) questionnaires were returned (Table 1).
History of any previous varicella infection from 2006 to
2011 varied between a maximum of 18% (2007) and a
minimum of 5% (2011; Table 1). During the period of
recommended one-dose varicella vaccination, coverage
of first-dose vaccinations was reported as 38% in 2006,
51% in 2007 and 53% in 2008 (see [24]). In July 2009,
the second dose was recommended; 1st dose coverage
increased from 53% in 2009 to 66% in 2010 and 68% in
2011 (Table 1, Figure 1). For second-dose varicella vacci-
nations, recorded since 2007, the overall rates were below
20% until 2008; after recommendation of the two-dose
schedule, second-dose vaccinations strongly increased (up
to 59% in 2011; Table 1, Figure 1). In varicella-vaccinated
children, use of solely tetravalent MMR-varicella vaccineTable 1 History of varicella and varicella vaccination coverag
years; absolute numbers and percentages
Parent survey on children 18-36 months of age 2006 200
(N questionnaires) (N = 372) (N = 3
History of any previous varicella disease; n (%) 47 (12.6) 66 (18
Vaccinated against varicella at time of survey
- received at least one dose; n (%) 140 (37.6) 187 (5
- received two doses; n (%) N.A. 37 (10
Data from BaVariPro Parent Surveys; 2006 to 2011.
*Mantel-Haenszel’s Chi2-Test for linear trend.was below 30% from 2006 to 2008 (2006: 2.2%, 2007:
19.0%, 2008: 28.7%), and increased strongly after 2008
(2009: 48.8%, 2010: 88.0%, 2011: 90.8%). During the total
observation period from 2006 to 2011, vaccination cover-
age for measles (1st dose) was between 86.9%, and 91.1%,
respectively (p-value for linear trend =0.163; Figure 1).Practice surveillance – characteristics of participating
practices and available reports
At the start of the practice surveillance in October 2006,
88 (67%) from 132 paediatric practices consented to par-
ticipate. In total, 98 (74%) Munich practices provided
practice questionnaires and monthly data during the sur-
veillance period.
At the start of surveillance, participating paediatricians
had practiced for an average of 21 years (median 20,
range 8-53). On average, a practice consisted of two phy-
sicians (median 2, range 1-4) and three consulting-room
assistants (median 3, range 0-7). Of the 98 practices, 22
(22%) treated up to 750 patients, 61 (62%) between 750
and 1,500 patients, and 15 (15%) more than 1,500 pa-
tients per month. During the quarter of the year prior to
start of surveillance, the practices performed an average
number of 30 routine well-baby visits (range 5-110) sched-
uled at an age of 10 to 12 months, and of 26 routine child
visits (range 2-70) scheduled at an age of 5-6 years. On
average, the practices had treated 23 varicella patients
(range 0-82) during the quarter prior to start of surveil-
lance, and had performed 23 vaccinations against varicella
(range 0-60) and 72 (range 5-200) against measles.
A total of 4,914 monthly reports, covering 4,558,682 pa-
tient contacts, were received from all participating prac-
tices during the five seasons, with 82 reports per month on
average (median 81, IQR 80-84, range 78-88 reports). From
these reports, 3,600 (73%) were provided by 60 practices
that reported data continuously during all 60 months of
surveillance. The results from this subgroup were consist-
ent with the results from the total sample.
For all cases with complications documented on the
monthly reports, additional single-case reports were
available (n = 134).e in children 18-36 months of age during five consecutive
7 2008 2009 2010 2011 p-
value*64) (N = 352) (N = 330) (N = 301) (N = 302)
.1) 39 (11.1) 26 (7.9) 23 (7.6) 15 (5.0) <0.001
1.4) 188 (53.4) 174 (52.7) 200 (66.4) 206 (68.2) <0.001
.2) 66 (18.8) 97 (29.4) 158 (52.5) 177 (58.6) <0.001
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Figure 1 Vaccination coverage for varicella (1st dose and 2nd
dose) and for measles (1st dose) in children 18-36 months of
age from annual parent surveys in the surveillance area
(Munich), in percent. In autumn 2008, licensure for all varicella
vaccines available in Germany was changed to a two-dose schedule.
Data from BaVariPro, parent surveys Nov 2006- Nov 2011.
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From October 2006 to September 2011, a total of 50,049
first-dose varicella vaccinations and of 40,541 second dose
vaccinations were administered (Table 2). First-dose vacci-
nations increased from a monthly average of 9.5 per 1,000
patient contacts in 2006/07 to 14.0 until 2008/09 and de-
creased slightly to 12.9 in 2010/11. Second dose vaccina-
tions were rare until 2007/08, with 1.0-2.2 per 1,000
patient contacts, increased to a monthly average of 15.1
per 1,000 patient contacts in 2008/09 after the change
in licensure for the monovalent vaccines to a two-dose
schedule in September 2008, and remained at 14.8-15.7
until 2010/11.
Until September 2008, monovalent varicella vaccine
was used in 83% and MMR-V vaccine (reimbursed until
then only in case of private health insurance) in 17% of
all first-dose vaccinations (Figure 2). From October 2008
to September 2011, 66%-86% of first dose vaccinations
were performed with MMR-V vaccine. For second dose
vaccinations, both monovalent (43%) and MMR-V vac-
cine (57%) were regularly administered (Figure 3).
The total number of all vaccinations (first and second
dose) with monovalent and with MMR-V vaccine differed
between age groups and seasons (Figure 4). In children <2
years of age, a total of 15,559 doses of monovalent varicella
vaccine were administered, with a strong decrease during
the observation period. In children 2-9 years of age, mono-
valent vaccine doses (n = 21,579) peaked during the 3rd
season 2008/09, and in children 10-16 years of age, mono-
valent vaccine doses (n = 2,530) increased over the seasons.
MMR-V doses were mainly administered in children <2
years of age (n = 42,610), with a strong increase after
September 2008. This increase was also observed in chil-
dren 2-9 years of age, with 7,532 MMR-V doses in total,including children who received MMR-V as the second
vaccination for measles and as the first vaccination for vari-
cella. Corresponding to the increase of MMR-V doses,
MMR doses in children <2 years of age (n = 39,089 doses)
and in children 2-9 years of age (n = 16,487 doses) de-
creased after September 2008.Practice surveillance - varicella cases and incidence estimates
From October 2006 to September 2011, the paediatri-
cians reported a total of 16,054 varicella cases showing a
typical annual pattern with peaks in spring of each year
(Table 3, Figure 5). Varicella cases decreased from 6,079
cases (a mean of 6.6 cases per 1,000 patient contacts) in
2006/07 to 1,464 cases (2.2 cases per 1,000 patient con-
tacts) in 2010/11, thus showing an overall decrease in
the mean number of cases by 67% during the five sea-
sons (Figure 5). The decrease occurred in two steps, and
was strongest between the first and second season (by 2.4
cases per 1,000 patient contacts). The number of varicella
cases reported in the seasons 2 and 3 were similar (decrease
of 0.25 per 1,000 patient contacts), followed by a further
pronounced decrease in season 4 (of 1.7 cases per 1,000 pa-
tient contacts), whereas season 5 was similar again to season
4 (decrease of only 0.1 cases per 1,000 patient contacts).
The majority of cases were observed in children <5 years of
age (Figure 6). The mean number of cases and their linear
trends for the age groups <1, 1-4, 5-9 and 10-16 years are
shown in Figure 7. During the five years of surveillance,
overall age-related reductions of 71% in children <1 year of
age, 75% in 1-4 year old children, 63% in 5-9 year-old chil-
dren, and 63% in 10-16 year old children were observed (for
the magnitude of changes in the different age groups from
each season to the next, see Table 4).
Minimum incidence estimates per 1,000 children <17
years of age, based on the number of reported cases, de-
creased by 76.9%, from 26.0 per 1,000 children <17 years
of age in the first season to 6.0 in the fifth season
(Table 5); for the age groups <1, 1-4, 5-9, and 10-16
years, the incidences decreased by 79.9%, 80.6%, 73.9%
and 47.4%, respectively. Taking into account paediatric
varicella cases occurring in paediatric and general practi-
tioner practices outside the surveillance project, as well
as children not seeking medical care, varicella incidences
were estimated approximately three times as high
(Table 5), with similar decreases assuming similar vac-
cination coverage.
A total of 1,076 (6.7%) varicella cases in vaccinated chil-
dren were documented, following the seasonal pattern of
varicella disease. A maximum of 314 cases (0.4 per 1,000
patient contacts) was reported in season 3 and a minimum
of 134 cases (0.2 per 1,000 patient contacts) in season 5
(Table 3). Absolute numbers of vaccinated cases were low-
est in season 4 and 5.
Table 2 Varicella vaccinations <17 years of age in Munich paediatric practices during five consecutive varicella seasons; absolute numbers and mean number
per 1000 patient contacts (with 95% confidence interval, CI)
Season 1 2 3 4 5 1-5
Surveillance period Oct 06-Sep 07 Oct 07-Sep 08 Oct 08-Sep 09 Oct 09-Sep 10 Oct 10-Sep 11 Oct 06-Sep 11
(N all monthly reports) (N = 1015) (N = 965) (N = 1013) (N = 974) (N = 947) (N = 4914)
Varicella vaccinations - all; 1st dose
- n 8234 9928 11872 10247 9768 50049
- mean per 1000 patient contacts (95%CI) 9.53 (9.03-10.03) 11.52 (10.96-12.09) 13.96 (13.30-14.63) 12.98 (12.32-13.65) 12.86 (12.25-13.48) 12.17 (11.89-12.44)
Varicella vaccinations - all; 2nd dose
- n 809 1703 13292 12967 11770 40541
- mean per 1000 patient contacts (95%CI) 0.98 (0.85-1.12) 2.17 (1.92-2.43) 15.12 (14.08-16.16) 15.68 (14.89-16.48) 14.76 (14.07-15.44) 9.72 (9.36-10.07)
Varicella vaccinations - monovalent; 1st dose
- n 6799 8289 3985 2095 1349 22517
- mean per 1000 patient contacts (95%CI) 7.73 (7.31-8.15) 9.43 (8.91-9.95) 4.32 (3.95-4.68) 2.71 (2.41-3.02) 1.93 (1.71-2.16) 5.25 (5.06-5.44)
Varicella vaccinations - monovalent; 2nd dose
- n 131 425 7524 5747 3553 17380
- mean per 1000 patient contacts (95%CI) 0.18 (0.12-0.24) 0.59 (0.42-0.75) 8.30 (7.52-9.08) 6.86 (6.35-7.37) 4.46 (4.13-4.78) 4.09 (3.86-4.31)
Varicella vaccinations - MMR-V; 1st dose
- n 1435 1639 7887 8152 8419 27532
- mean per 1000 patient contacts (95%CI) 1.80 (1.60-2.00) 2.10 (1.88-2.31) 9.66 (9.12-10.20) 10.30 (9.74-10.85) 10.95 (10.40-11.51) 6.93 (6.70-7.16)
Varicella vaccinations - MMR-V; 2nd dose
- n 678 1278 5768 7220 8217 23161
- mean per 1000 patient contacts (95%CI) 0.80 (0.69-0.92) 1.59 (1.41-1.76) 6.84 (5.90-7.31) 8.86 (8.36-9.37) 10.30 (9.77-10.83) 5.64 (5.43-5.84)
Data from BaVariPro Practice Surveillance; Oct 2006-Sep 2011.
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Figure 2 Varicella vaccinations (1st dose), average per month and practice. Stacked bars show proportion of monovalent varicella vaccine
(black, n = 22,517) and of tetravalent MMR-V vaccine (grey, n = 27,532). The arrow indicates the change to a two-dose schedule for all licensed
varicella vaccines. Data from BaVariPro, practice surveillance Oct 2006-Sep 2011.
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http://www.biomedcentral.com/1471-2334/13/303Complications of varicella occurred in 134 (0.8%) practice
patients (Table 3) and also peaked in spring of each year.
During all five seasons, complicated cases were observed in
the range of 0.03 to 0.07 cases per 1,000 patient contacts
(Table 3). From all 134 patients, 86 (64.2%) were <5 years of
age, 46 (34.3%) were 5 to 9 years old, and 2 (1.5%) 10 to 16
years old; across all five seasons, complications were most
frequent in children <5 years of age. For 11 (8.2%) patients
with complications, an underlying chronic disease was doc-
umented. For all 134 patients, a total of 190 specific0
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(n = 66) and otitis media (n = 45). Complications of the cen-
tral nervous system were observed in nine children (3/1/2/
2/1 in seasons 1 to 5), along with encephalitis (n = 2), men-
ingitis (n = 2), febrile convulsions (n = 2), cerebellitis (n = 1),
status epilepticus (n = 1), and strong headaches (n = 1).
Seventeen (12.7%) from 134 children with complications
were breakthrough varicella cases >42 days after one-dose
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http://www.biomedcentral.com/1471-2334/13/3030.1% in vaccinated children, compared to 0.7% in unvaccin-
ated children. From a total of nine patients with complica-
tions of the central nervous system, two (22%) occurred in
children with breakthrough varicella after a single dose (fe-
brile convulsions).
Hospitalisation was reported for 23 practice patients
(8/4/4/3/4 in seasons 1 to 5), corresponding to 0.1% of
all 16,054 patients captured by the practice surveillance
and 17% of all 134 patients with complications. Five of
the hospitalized children were breakthrough varicella
cases at least 7 months after vaccination, including two
children with underlying chronic disease (one child with
neurodermitis had a complicated febrile seizure, the
other was a child with pre-existing HIV infection hospi-
talized for acyclovir therapy). No fatalities occurred; forTable 3 Varicella cases in children <17 years of age in Munich
seasons; absolute numbers and mean number per 1000 patie
Season 1 2
Surveillance period Oct 06-Sep 07 Oct 07-Sep 08
(N all monthly reports) (N = 1015) (N = 965)
Varicella cases - all
- n 6079 3518
- mean per 1000 patient contacts (95%CI) 6.58 (6.14-7.03) 4.20 (3.85-4.55
Varicella cases - vaccinated
- n 218 231
- mean per 1000 patient contacts (95%CI) 0.27 (0.22-0.32) 0.32 (0.24-0.40
- % of all varicella cases 3.6 6.6
Varicella cases - with complications
- n 31 20
- mean per 1000 patient contacts (95%CI) 0.04 (0.02-0.06) 0.03 (0.01-0.05
- % of all varicella cases 0.5 0.6
Data from BaVariPro Practice Surveillance; Oct 2006-Sep 2011.five (3.7%) of all 134 children (0.03% of all 16,054 chil-
dren) permanent scars were documented.
Hospital databases – patient characteristics and
hospitalisation incidence
From 2005 to 2009, a total of 178 varicella patients were
reported from the hospitals. For the years 2005 and 2006
three out of all four Munich paediatric hospitals, cover-
ing 88% of all paediatric hospital beds in the area, pro-
vided data (28 patients in 2005, 34 in 2006); for the
years 2007 to 2009, data were available from all four
hospitals (62 in 2007, 31 in 2008, 23 in 2009).
The majority (116; 65.2%) were <5 years of age (in-
cluding 38 children <11 months of age), 47 (26.4%) were
5 to 9 years old, and 15 (8.4%) were 10 to 16 years ofpaediatric practices during five consecutive varicella
nt contacts (with 95% confidence interval)
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http://www.biomedcentral.com/1471-2334/13/303age; 90 (50.6%) were male children. In 162 (92.3%) children
the primary diagnosis either was varicella (82; 46.1%) or a
known complication of varicella disease (70; 39.3%) or indi-
cated that the child belonged to a risk group for severe vari-
cella (10; 5.6%). A total of 21 (11.8%) patients suffered from
an immunocompromising condition. Complications of the
central nervous system were reported in 40 (22.5%) pa-
tients, including febrile convulsions (12), other convulsions
(7), encephalitis (7), syncope / collapse (3), and facial paraly-
sis (3) as the most frequent neurological complications.
Fifty-seven (32.0%) patients had gastrointestinal complica-
tions (mainly difficulties to feed or drink / dehydration;
n = 32). Also frequent were complications of the skin in 28
(15.7%) patients (mainly local skin infections; n = 18), and
of the lower respiratory tract in 16 (9%) patients, including
eight children with varicella-associated pneumonia. Median0
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Figure 6 Varicella cases (n = 16,054) per age group, during 5 varicella
08-Sep 09, n3 = 3215; Oct 09-Sep 10, n4 = 1778; Oct 10-Sep 11, n5 = 1duration of hospital stay was 3 days (IQR 2-6). One fatality
was reported in an 8-months-old girl with varicella pneu-
monia suffering from pre-existing chronic conditions
(severe perinatal asphyxia, microcephaly / hydrocephaly,
cardiac defect), admitted in July 2009 with acute respiratory
distress syndrome; death occurred after one day in the
hospital.
Out of all 178 varicella patients treated in Munich paedi-
atric hospitals, 113 (63.5%) had a postal code compatible
with the complete surveillance area Munich City and its
surrounding districts; 105 of these were varicella-related
hospitalisations, including 71 with a specific postal code for
Munich City. With an estimate of two additional patients
each in 2005 and 2006 for the non-participating hospital,
incidence calculation of varicella-associated hospitalisations
was based on a total number of 75 patients. From 2005 to4 <5 5-9 10-16
up (years)
8-Sep 09 Oct 09-Sep 10 Oct 10-Sep 11
n=3085
n=9631
n=5844
n=579
seasons (Oct 06-Sep 07, n1 = 6079; Oct 07-Sep 08, n2 = 3518; Oct
464). Data from BaVariPro, practice surveillance Oct 2006-Sep 2011.
Figure 7 Model-fitted mean number of varicella cases per reporting unit (paediatric practice) by age group (<1, 1-4, 5-9, 10-16 years
of age), with linear trends per age group from five varicella seasons (n tot. =16,054). Data from BaVariPro, practice surveillance Oct
2006 – Sep 2011).
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http://www.biomedcentral.com/1471-2334/13/3032008, incidence per 100,000 children <17 years of age
varied between 7.6 and 12.1, and decreased to 4.3 in
2009 (by 43% since 2005; Table 6). For the age group <5
years of age, hospitalisation incidences were between
15.2 and 21.2 until 2008 and decreased to 4.7 in 2009 (by
78% since 2005; Table 6). The strongest decrease was ob-
served in children <1 year of age, from a maximum inci-
dence of 60.8 in 2005 to a minimum of 14.2 in 2009 (by
77% since 2005; Table 6).
Matching of hospital and paediatric practice patients
For season 2 and 3 from the practice surveillance (Oct
2007 to Sep 2009), a total of 23 varicella patients (16 and 7
respectively) fromMunich City were reported from all four
hospitals. For season 2, 12 (75%) out of 16 hospital patients
had either not contacted a paediatrician or were patients
from practices not covered by the surveillance. For season
3, six (86%) out of seven hospital patients had not been
captured by the practice surveillance.Table 4 Relative reduction factors (RRF) for varicella cases
per age group (model-predicted, see Höhle et al. 2010)
Ratio RRF RRF RRF RRF
Season 2 /
Season 1
Season 3 /
Season 2
Season 4 /
Season 3
Season 5 /
Season 4
Age group (years)
<1 0.698 0.743 0.670 0.815
1-4 0.676 0.749 0.594 0.847
5-9 0.732 0.906 0.660 0.842
10-16 0.856 0.908 0.868 0.927
Data from BaVariPro Practice Surveillance, Oct 2006-Sep 2011.Discussion
This is the first study in Germany and Central Europe pro-
viding incidence estimates for changing varicella epidemi-
ology after recommendation of routine vaccination. In a
defined surveillance area, data on children collected from
parents, paediatric practices and hospitals indicated in-
creasing acceptance of vaccination and a clear decrease of
the burden of varicella infections and complications.
After the recommendation in 2004, coverage in children
up to three years of age in the surveillance area increased
markedly (in two steps) during the observation period.
During the one-dose vaccination schedule recommended
until June 2009, varicella vaccination coverage at first in-
creased to 51% in 2007 but then stagnated at 53% in 2008
[24] and 2009. During that first period, statutory reim-
bursement regulations in the surveillance area only cov-
ered the use of monovalent varicella vaccines (applicable in
one dose). Combined MMR-varicella vaccine (applicable in
two doses) was reimbursed by private health insurance
only and was used in less than 20% of first-dose varicella
vaccinations. After the recommendation of a two-dose
schedule in 2009 and the resultant reimbursement also for
the two-dose MMR-varicella vaccine, the combined vac-
cine was strongly preferred. In the last observed season of
practice surveillance (Oct 2010-Sep 2011) more than 85% of
all first-dose dose varicella vaccinations were performed
with combined vaccine, and in the last parent survey (Nov
2011), more than 90% of the vaccinated children had re-
ceived it. This is very likely due to the fact that vaccinations
against MMR are generally well accepted, and that by the
use of combination vaccines additional injections can be
avoided [6,26-28]. Presumably due to this better acceptance,
Table 5 Seasonal incidence estimates of varicella cases per 1000 children 0-16 years of age in the area of Munich, by
age group; a) minimum incidence estimate based on observed cases in paediatric practices, b) incidence estimate
taking into account estimates on varicella cases from non-participating paediatric practices, general practitioners, and
cases without physician consultation
Season 1 2 3 4 5 1-5
Surveillance period Oct 06-
Sep 07
Oct 07-
Sep 08
Oct 08-
Sep 09
Oct 09-
Sep 10
Oct 10-
Sep 11
Oct 06-
Sep 11
a) Incidence /1000; based on observed numbers of cases in the
participating practices (minimum incidence)
<1 year of age
- n 372 182 168 96 81 899
- incidence 23.4 10.9 9.8 5.6 4.7 10.7
1-4 years of age
- n 3494 2004 1652 845 737 8732
- incidence 58.7 33.2 26.7 13.3 11.4 28.2
5-9 years of age
- n 2039 1226 1273 752 554 5844
- incidence 29.9 18.0 18.6 10.9 7.8 16.9
10-16 years of age
- n 174 106 122 85 92 579
- incidence 1.9 1.2 1.3 0.9 1.0 1.3
<17 years of age (all cases)
- n 6079 3518 3215 1778 1464 16054
- incidence 26.0 14.9 13.5 7.4 6.0 13.4
b) Incidence /1000; corrected for cases from non-participating practices in the respective
season*, cases from general practitioner practices#, and untreated cases§ (estimates)
<17 years of age (all cases)
- n 18244 11106 9667 5561 4710 49288
- incidence 78.1 47.1 40.6 23.0 19.2 41.3
Data from BaVariPro Practice Surveillance, Oct 2006-Sep 2011.
*: assuming that, on average, a participating and a non-participating paediatric practice contribute similar numbers of varicella cases in each season.
#: assuming that cases from general practitioner practices represent approximately 35% of all varicella cases treated by a physician.
§: assuming that, on average, untreated cases represent approximately 20% of all paediatric varicella cases in each season (Streng et al. [24]).
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http://www.biomedcentral.com/1471-2334/13/303a second pronounced increase in first-dose varicella vaccin-
ation coverage up to 66% was observed in 2010. However,
coverage stagnated again, at 68% in 2011. This is consider-
ably below the advisable coverage level of 85%-90% to avoid
a potential shift in the age-related incidence towards older
children and adults [29]. In contrast, vaccination against
measles was consistently high during the observation period
(first dose coverage 86%-91%), indicating that a considerable
proportion of parents (23% in 2011) accepted vaccination
against measles but neither separate nor combined vaccin-
ation against varicella.
The two pronounced increases in coverage were each
followed by two marked decreases in the number of
paediatric varicella cases, from 6.6 to 4.2 cases per 1,000
patient contacts (season 1 to 2) and from 4.0 to 2.3 cases
(season 3 to 4), with an overall decrease of 67% of all
cases during the five-year observation. The strongest de-
crease (by 75%) was observed in children below fiveyears of age, i.e. the age group most frequently affected by
varicella disease in unvaccinated populations [1]. Children
below one year of age, 80% of whom are not yet varicella-
vaccinated [24], and older children and adolescents also
showed a considerable decrease (71% and 63%, respect-
ively), indicating herd protection effects. The overall de-
crease in incidence was 77% for all children.
In the participating practices, covering about two-thirds
of all paediatric practices in the area, varicella complica-
tions were rarely observed (<1% of all varicella cases), and
the practices reported only 23 hospitalisations during the
five-year observation period. However, the practice surveil-
lance only captured 14% to 25% of all varicella cases treated
in the paediatric hospitals in the surveillance area, indicat-
ing that a considerable proportion of complicated cases
presented directly at the hospitals without the paediatrician
being aware of this fact. Thus, the true burden of varicella
complications and hospitalisations may be underestimated
Table 6 Annual incidences of varicella-associated
hospitalisations per 100,000 children (Munich City) 0-16
years of age, from Munich paediatric hospitals,
by age group
Year of
hospitalisation
2005 2006 2007 2008 2009 2005-2009
<1 year of age
- n 8 3 5 4 2 22
- incidence /100,000 60.8 26.2 36.5 28.6 14.2 32.5
<5 years of age
- n 12 9 13 12 3 49
- incidence /100,000 21.0 15.2 21.2 19.0 4.7 15.9
<17 years of age
(all cases)
- n 14 17 22 14 8 75
- incidence /100,000 7.6 9.4 12.1 7.6 4.3 8.2
Data from BaVariPro Hospital Databases, 2005-2009.
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http://www.biomedcentral.com/1471-2334/13/303by surveillance systems based on practices only. Our data
confirm the strong underreporting of hospitalisations
already suspected for the German sentinel surveillance,
where about 900 practices reported only 71 hospitalisations
during four years of observation [30]. The data collected dir-
ectly from the hospitals in our surveillance area showed a
strong impact of vaccination on the incidence of varicella-
related hospitalisations, which decreased by 43% during five
years. It should be noted that the 5 years of hospital surveil-
lance started earlier than the other parts of the project and
the last data were collected in 2009. Thus, the hospital data
were collected largely during the one-dose vaccination
schedule; nevertheless, considerable reductions of these
more severe cases were already observed (by 78% in chil-
dren <5 years of age). This confirms results from other stud-
ies indicating the high effectiveness of varicella vaccination
for prevention of severe cases [e.g., 15]. The only varicella-
associated fatality observed during the study occurred in an
8-months-old child with severe underlying chronic disease,
thus indicating the importance to vaccinate close contacts
of persons at high risk for serious varicella complications.
Vaccinated varicella cases were rare (on average, 7% of all
cases) and, after initial increase, remained stable at a propor-
tion of 9%-10% after season 3. At the end of season 3, the
second dose had been recommended. Vaccinated cases after
two doses usually occur less frequently than after a single
dose [31]. The reduction observed after season 3 may be ei-
ther due to the boosting effect of the second dose [32] dur-
ing that time, or a result of a general increase in varicella
vaccination coverage in the population. Due to the high ef-
fectiveness of varicella vaccines and the resultant decrease
of unvaccinated cases, the proportion of vaccinated cases is
expected to further increase over time [18].
Compared to German regions with earlier reimburse-
ment of one- and two-dose varicella vaccinations, andhence presumably higher coverage, the impact of the
vaccination programme was delayed in our surveillance
region [20,23]. During four years of observation (2005/
2006 until 2008/2009) and including all age groups,
German sentinel surveillance found a largely continuous
reduction of annual varicella cases, with a total decrease
by 63% of all cases [30], which preceded the similar de-
crease observed in our population by about two years.
The difference is most likely due to the delay in reim-
bursement for vaccination in Bavaria, and demonstrates
that besides the recommendations which were equal
throughout Germany, reimbursement of vaccine is cru-
cial to obtain the necessary coverage for control of
varicella.
From Europe, a study from the Veneto region (Italy), in-
vestigated the effectiveness of two-dose varicella vaccin-
ation introduced in 2005, with the first dose in the second
year of life and a second dose at the age of six years [33]. In
this region, vaccination was well accepted and 79% first-
dose coverage was reached in the 2008 birth cohort, with
MMR-varicella vaccine being used in up to 92% of all vac-
cinations. Up to 64% decrease of paediatric varicella inci-
dence and 53% of varicella hospitalisations were observed
there until 2008 [33]. Further impact data are available
from the Sicily region, where universal vaccination was in-
troduced in 2003, with a coverage >85% and a decrease in
paediatric incidence by >90% to 2007 [34]. A rapid and
steep reduction in the incidence (by up to 96%) as well as
in hospital admissions (by 71%) was also observed in the
Navarre region (Spain) to 2010, where universal vaccin-
ation was introduced in 2007 [35]. Although seropreva-
lence studies indicated a lower age at varicella infection in
Germany compared to Italy and Spain [34,36], and vac-
cination programmes differed in time and pattern of
introduction, age at vaccination, acceptance and surveil-
lance systems, routine varicella vaccination appears
highly effective in all European regions investigated
so far.
Apart from Europe and the USA, similarly high impact
of publicly funded, mainly single-dose, routine varicella
vaccination programmes in early childhood was reported
in Uruguay [7] and more recently in Taiwan [37], Australia
[38,39], Canada [40] and Costa Rica [41] (Table 7). In all
these countries, higher levels of coverage were reached
earlier, and stronger reductions found in a shorter time
than in both German surveillance systems, reflecting a
more reluctant attitude towards varicella vaccination by
physicians and parents in Germany [24].
A potential limitation of our practice surveillance study
is that although the majority of all paediatric practices in
the area participated, these practices may not be fully rep-
resentative of the population investigated. Practices with a
more negative attitude towards varicella vaccination may
not have participated in the surveillance, and, hence, in
Table 7 Review on the impact of nation-wide, publicly funded, mainly one-dose, routine varicella vaccination programmes in early childhood in countries
outside Europe and the US
Authors Year of publication Country Nationwide routine varicella
vaccination implemented (year)
Coverage Decrease in varicella patients reached (year)
Quian et al. [7] 2008 Uruguay 1999 >90% in 2005 Outpatient visits by 87%, hospitalisations by 81% (2005)
Chao et al. [37] 2012 Taiwan 2004 >90% after 2006 Incidence by 53% (2008)
Carville et al. [38], 2010 Australia 2005 82% in 2009 Hospitalisation rates / community consultations by 7% (2007),
congenital varicella by 100%, neonatal varicella by >85%
(2008/2009)Khandaker et al. [39] 2011
Tan et al. [40] 2012 Canada 2007 58%-90% in 2008 Hospitalisations by 81%-86% (2008)
Ulloa-Gutierrez et al. [41] 2011 Costa Rica 2007 n.a. Paediatric cases by 83% (2010)
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http://www.biomedcentral.com/1471-2334/13/303those practices the average number of varicella cases may
have been higher, potentially resulting in an underestima-
tion of varicella incidence. Paediatricians and parents in
the surveillance area may differ in their attitude towards
varicella vaccination from other German regions, for which
a higher coverage had been estimated [20,22]. The practice
surveillance was based on observation of clinical varicella
cases without laboratory confirmation; hence, mild cases in
vaccinated children may have been underreported. Vari-
cella hospitalisations assessed by ICD-10 based data from
hospitals were not confirmed by chart review. However,
misclassification seems to be unlikely due to the typical
clinical diagnosis of varicella.
The WHO recommended in 1998: “Routine childhood
immunization against varicella may be considered in coun-
tries where this disease is a relatively important public
health and socioeconomic problem, where the vaccine is
affordable, and where high (85%-90%) and sustained vac-
cine coverage can be achieved” [29]. In the USA, a cover-
age level of 85% was reached in the year 2003, seven years
after the initial recommendation of a one-dose schedule.
This may be partly due to implementation of day-care and
school entry requirements for varicella vaccination [42]. In
Germany and other European countries without such re-
quirements, high coverage levels may be more difficult to
achieve, and increased use of combined MMR-V vaccine
might help to reach this goal. However, data on both the
MMR-V vaccine used in the USA (Proquad®, manufactured
by Merck, Whitehouse Station, NJ, USA) and the one
used in Germany (Priorix Tetra®, manufactured by
GlaxoSmithKline, Wavre, Belgium) indicated a slightly
increased risk of febrile seizures at a period of 5 to 12
days after receipt of the first dose (estimated as approxi-
mately one additional febrile seizure per 2000 first-dose
MMR-V vaccinations) compared to simultaneous but
separate first-dose vaccination with MMR and monova-
lent varicella vaccine. Hence, the Advisory Committee
on Immunization Practices in the USA recommended
separate application of MMR and varicella vaccine for
the first dose in 2010 [43]; the German STIKO gave a
similar recommendation in September 2011 [44]. As ob-
served in Munich during the previous period of vaccin-
ation mainly with monovalent varicella vaccines, it could
be expected that some parents might again not accept
this additional injection. Indeed, recent data from our
surveillance project showed that first-dose varicella vac-
cinations decreased by 12% in the Munich paediatric
practices during the year following the recommendation
in 2011, whereas first-dose MMR vaccinations remained
on the same level as the previous MMRV vaccinations
(Streng et al., unpublished). This may contribute to stag-
nating varicella vaccine coverage and, over time, result
in an increasing number of children with missing or
incomplete protection at least in some regions ofGermany. The potential consequences of such a vaccin-
ation pattern on varicella zoster virus epidemiology in
Germany - such as disease resurgence or a shift to older
age at infection - will have to be monitored closely.
Long-term monitoring, as it has been suggested by a re-
cent evaluation of the German varicella vaccination pro-
gram [45], will be facilitated, as varicella was made a
notifiable disease in Germany in March 2013 [46].
Conclusions
After introduction of routine varicella vaccination in 2004,
coverage increased up to 68% until 2011 in the surveillance
area. Correspondingly, paediatric varicella cases decreased
by 67% and paediatric hospitalisations by 43%. Preferential
use of combined MMR-varicella vaccine since 2009 was
linked to a marked increase in coverage. As MMR-V is cur-
rently not recommended for first-dose varicella vaccination,
it may be difficult to maintain the present coverage levels or
achieve higher coverage necessary for sustained control of
varicella. Continuous surveillance of the varicella epidemi-
ology and continuous evaluation of the current recommen-
dations is needed to monitor the long-term effectiveness of
varicella vaccination.
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